


PIM1-IN-1

Cat. No.:	HY-111552		
CAS No.:	1417630-95-5		
Molecular Formula:	C ₂₅ H ₃₀ N ₈ O ₂		
Molecular Weight:	474.56		
Target:	Pim		
Pathway:	JAK/STAT Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 45 mg/mL (94.82 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.1072 mL	10.5361 mL	21.0722 mL
	5 mM	0.4214 mL	2.1072 mL	4.2144 mL
	10 mM	0.2107 mL	1.0536 mL	2.1072 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

PIM1-IN-1 is a potent and highly selective PIM1/3 inhibitor, with IC₅₀s of 7, 5530 and 70 nM for PIM1, PIM2, and PIM3, respectively, inhibits the phosphorylation of BAD, a downstream target of PIM, with an EC₅₀ of 262 nM. PIM1-IN-1 shows no obvious effect on FLT3 or hERG binding. Antiproliferative and anti-cancer activity^[1].

IC₅₀ & Target

PIM1 7 nM (IC ₅₀)	PIM3 70 nM (IC ₅₀)	PIM2 5530 nM (IC ₅₀)
----------------------------------	-----------------------------------	-------------------------------------

In Vitro

PIM1-IN-1 (Compound 42) exhibits antiproliferative activity, with GI₅₀ of 1.48 μM for melanoma cell line SKMEL-19. PIM1-IN-1 has significant synergistic effect combined with different antitumoral agents in different tumor cell lines^[1]. PIM1-IN-1 (2.5, 5, or 10 μM, 24 hours) induces apoptosis in SKMEL19 cells^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:	SKMEL19 cells
------------	---------------

	Concentration:	2.5, 5, or 10 μ M
	Incubation Time:	24 hours
	Result:	Regulated cell cycle, induced cell apoptosis in SKMEL19 cells.
In Vivo	PIM1-IN-1 shows acceptable clearance of 1.26 L/h/kg in BALB-C mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

[1]. Martínez-González S, et al. Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors. Eur J Med Chem. 2019 Feb 19;168:87-109.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA